<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04881019</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-20-7635</org_study_id>
    <nct_id>NCT04881019</nct_id>
  </id_info>
  <brief_title>PRediction Of Glycemic RESponse Study</brief_title>
  <acronym>PROGRESS</acronym>
  <official_title>Prediction of Glycemic Response Study (PROGRESS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scripps Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tempus Labs</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CareEvolution Healthcare Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Scripps Translational Science Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of PROGRESS is to engage and intensively monitor 1000 individuals' dietary&#xD;
      intake, activity levels, and continuous glucose values over 10 days, link to clinical events&#xD;
      out to 3-years, and use that data along with genomic, microbiome, electronic health record&#xD;
      (EHR), and other biomarker data to develop a predictive model of individual glucose responses&#xD;
      to nutrient intake in individuals with and without type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interested individuals will be directed to download the MyDataHelps™ (CareEvolution) mobile&#xD;
      app to register and provide informed consent as well as prompt completion of surveys, share&#xD;
      their electronic health record data and link the digital health technologies to be used in&#xD;
      the study. Participants may be asked to schedule an initial virtual meeting (telephone or&#xD;
      videoconference) with the research coordinator who will welcome and walk them through the&#xD;
      study.&#xD;
&#xD;
      Once a participant has completed on-boarding, they will be asked to fill out a baseline&#xD;
      health, lifestyle, and medical history surveys and, upon completion, invited to request a&#xD;
      biosamples study kit to be delivered to their home. This biosamples kit will include:&#xD;
&#xD;
        -  Salivary kit for genomics analysis&#xD;
&#xD;
        -  Gut microbiome kit&#xD;
&#xD;
        -  Home micro-puncture single-use blood collection&#xD;
&#xD;
      Additional study materials and devices include:&#xD;
&#xD;
        -  A wrist-worn activity, heart rate and sleep monitor.&#xD;
&#xD;
        -  A Dexcom 6 continuous glucose monitor (CGM) and application kit&#xD;
&#xD;
        -  A standardized snack bar meal (2 per fasting days)&#xD;
&#xD;
      Participants will be asked to track various digital health measures including their&#xD;
      continuous glucose as well as record their meals for a 10-day period. The data connections&#xD;
      approved by the participants will continue in the following years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gylcemic response profiles</measure>
    <time_frame>10-days</time_frame>
    <description>Distinguish differences in individual glycemic response characteristics as measured by the continuous glucose monitor (mg/dl) and macronutrients (carbohydrates, fats, and proteins) in participants with (n = 500) and without type 2 diabetes (n = 500) matched for age, sex, BMI.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Glycemic Response</condition>
  <arm_group>
    <arm_group_label>Type 2 Diabetes</arm_group_label>
    <description>Individuals who have been diagnosed with Type 2 diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non type 2 diabetes</arm_group_label>
    <description>Individuals who have not been diagnosed with Type 2 diabetes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous glucose monitoring</intervention_name>
    <description>Continuous monitoring of blood sugar over a 10-day period.</description>
    <arm_group_label>Non type 2 diabetes</arm_group_label>
    <arm_group_label>Type 2 Diabetes</arm_group_label>
    <other_name>Dexcom G6</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva and stool for genetic and microbiome analyses, respectively.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study participants will be composed of 50% individuals with diagnosed T2D (using a&#xD;
        validated algorithm) and 50% individuals without a formal diagnosis of T2D and who have a&#xD;
        documented HgbA1C &lt; 6.5 within the prior 2 years, matched to the T2D cohort based on age,&#xD;
        gender, and BMI.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  Unable to participate in or comply with any of the testing modules asked during the&#xD;
             study&#xD;
&#xD;
          -  Currently pregnant&#xD;
&#xD;
          -  Prior bariatric surgery&#xD;
&#xD;
          -  Chemotherapy or radiation treatment for cancer in the past year&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Known skin allergy to adhesives and nickel (or other contraindications to continuous&#xD;
             glucose monitoring)&#xD;
&#xD;
          -  Currently taking any oral steroids(these medications may impact glucose levels)&#xD;
&#xD;
          -  Antibiotic use in the last 3 months prior to the start of the study or planned use&#xD;
             during the duration of the study&#xD;
&#xD;
          -  Non-dietary, supplemental probiotic use either daily or weekly&#xD;
&#xD;
          -  Hospice care&#xD;
&#xD;
          -  End stage renal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Ramos, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Coordinator</last_name>
    <phone>858.784.2272</phone>
    <email>progress@scripps.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scripps Research Translational Institute</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Scripps Translational Science Institute</investigator_affiliation>
    <investigator_full_name>Ed Ramos</investigator_full_name>
    <investigator_title>Director, Digital Clinical Trials</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

